John Anthony Hadfield

Incanthera Research & Development Ltd. develops drug delivery solutions for solid tumor chemotherapy. It offers cancer therapies, such as ICT01-2588, a vascular disrupting agent and drug delivery platform for lung and prostate cancer; and ICT03-Es5, a bioreductive anticancer agent for lung, liver, and breast cancer. The company was founded by Alan McGowan, Paul Loadman, Laurence Patterson, Andrew John Michael Duley, John Anthony Hadfield, Robert Falconer, and Jason Gill in 2010 and is headquartered in Manchester, the United Kingdom.

Incanthera Oncology Ltd. engages in the provision of drug development services. The company was founded on April 7, 2011 and is headquartered in Manchester, the United kingdom.